. 2015 May 19;13:61. doi: 10.1186/s12955-015-0261-1

Table 2.

Results for health-related quality of life from the QLQ-C30

Dimensions		Capecitabine-based				5-FU/LV-based				P value^b
Dimensions		n	Mean	SD	P value^a	n	Mean	SD	P value^a	P value^b
Physical
	Baseline	81	73.90	11.78		27	80.12	12.46		0.746
	28th week	81	86.14	11.13	<0.0001	27	86.12	11.48	0.038	0.657
Role
	Baseline	81	78.58	11.65		27	77.48	14.78		0.865
	28th week	81	90.97	11.08	<0.0001	27	86.77	14.31	0.001	0.582
Emotional
	Baseline	81	84.45	8.54		27	83.88	7.57		0.537
	28th week	81	90.24	7.56	<0.0001	27	89.93	6.10	<0.0001	0.357
Cognitive
	Baseline	81	88.18	7.42		27	88.58	8.30		0.091
	28th week	81	92.55	7.29	<0.0001	27	87.77	6.93	0.641	0.331
Social
	Baseline	81	83.15	8.58		27	82.75	11.85		0.313
	28th week	81	84.86	9.06	0.226	27	91.03	8.98	0.002	0.532
Global health status
	Baseline	81	62.93	6.59		27	59.61	8.98		0.517
	28th week	81	75.58	5.64	<0.0001	27	74.76	4.97	<0.0001	0.854
Fatigue
	Baseline	81	25.11	10.49		27	25.80	8.81		0.884
	28th week	81	9.34	10.53	<0.0001	27	17.59	9.63	0.002	0.259
Nausea and Vomiting
	Baseline	81	3.91	9.41		27	6.77	10.74		0.467
	28th week	81	6.56	9.96	0.002	27	6.81	10.89	0.982	0.187
Pain
	Baseline	81	11.75	8.36		27	8.41	7.61		0.421
	28th week	81	4.63	6.24	<0.0001	27	4.07	6.13	0.058	0.746
Dyspnea
	Baseline	81	8.82	8.62		27	6.00	9.61		0.087
	28th week	81	6.64	5.13	0.029	27	4.90	8.52	0.536	0.689
Insomnia
	Baseline	81	22.16	15.78		27	18.50	13.71		0.050
	28th week	81	16.15	11.96	0.002	27	17.19	11.73	0.603	0.382
Appetite loss
	Baseline	81	10.44	10.91		27	19.64	12.17		0.004
	28th week	81	11.10	14.75	0.696	27	11.67	16.08	0.006	0.476
Constipation
	Baseline	81	14.31	12.40		27	6.36	11.67		0.057
	28th week	81	14.28	7.64	0.982	27	6.24	6.53	0.951	0.273
Diarrhea
	Baseline	81	13.88	16.39		27	13.82	14.39		0.581
	28th week	81	9.05	14.78	0.002	27	12.91	13.16	0.783	0.276
Financial difficulties
	Baseline	81	6.06	6.70		27	7.45	7.24		0.666
	28th week	81	6.05	10.20	0.990	27	4.83	10.33	0.118	0.040

^a Paired t-test was used to calculate the statistical significance at the 5 % level between the adjusted means at baseline and the 28th week

^b Mixed model was used to calculate the statistical significance at the 5 % level following adjustment for patient age, gender, education, marital status, work status, tumor site, family history, comorbidities, use of oxaliplatin, and baseline HRQoL score